Enriched Clinical Trial Design: Who Gets Left Behind?
Enriched clinical trial design can improve trial efficiency, but may exclude patients from the evidence base. Explore the implications for clinical development.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Enriched clinical trial design can improve trial efficiency, but may exclude patients from the evidence base. Explore the implications for clinical development.
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
BMS and NVIDIA are building a powerful pharma AI factory using advanced supercomputing, AI models, and scientific data to accelerate drug discovery.
Robotics in pharmaceutical manufacturing is strengthening GMP through automation, contamination control, traceability, and more consistent production processes.
FDA oncology clinical trial guidance targets restrictive eligibility criteria, covering performance status, washout periods, medications, and laboratory values.
EHR patient recruitment could improve clinical trial matching, but workflow integration, data quality, interoperability, and AI validation remain key challenges.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
Read about how Throne Science is advancing passive health monitoring with AI-powered sensing that automatically captures daily toilet habit data.
Data integrity and ALCOA principles are under new pressure as digital twins, AI, and continuous manufacturing reshape pharma production and quality control.
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."
Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
See how cold chain optimisation can reduce pharmaceutical logistics costs, emissions, and product risk by modelling uncertainty across storage and distribution.